Table 1.
Characteristics at ART initiation among adults with HIV who initiated treatment and had CD4+ cell count in Ethiopia, Kenya, Mozambique and Tanzania 2005 to 2015 (N = 305,443)
| All | CD4+ count at ART initiation | ||||
|---|---|---|---|---|---|
| >200 | 100 to 199 | 50 to 99 | <50 | ||
| N (%) | N (%) | N (%) | N (%) | N (%) | |
| 305,443 (100.0) | 118,580 (38.8) | 91,788 (30.1) | 44,029 (14.4) | 51,046 (16.7) | |
| Median CD4 count at ART (IQR) | 164 (78 to 255) | 285 (237 to 349) | 151 (125 to 176) | 75 (62 to 87) | 20 (7 to 35) |
| Country | |||||
| Ethiopia (73 sites) | 71,601 (23.4) | 20,296 (17.1) | 26,109 (28.4) | 13,303 (30.2) | 11,893 (23.3) |
| Kenya (125 sites) | 91,980 (30.1) | 39,151 (33.0) | 24,108 (26.3) | 11,701 (26.6) | 17,020 (33.3) |
| Mozambique (67 sites) | 93,541 (30.6) | 40,256 (33.9) | 27,550 (30) | 12,424 (28.2) | 13,311 (26.1) |
| Tanzania (85 sites) | 48,321 (15.8) | 18,877 (15.9) | 14,021 (15.3) | 6601 (15.0) | 8822 (17.3) |
| Sex | |||||
| Female | 195,062 (63.9) | 82,223 (69.3) | 58,267 (63.5) | 25,819 (58.6) | 28,753 (56.3) |
| Male | 110,381 (36.1) | 36,357 (30.7) | 33,521 (36.5) | 18,210 (41.4) | 22,293 (43.7) |
| Age at enrolment in HIV care | |||||
| Median (IQR) | 34.5 (28.0 to 42.0) | 33.2 (27.0 to 41.6) | 35.0 (28.4 to 42.2) | 35.0 (29.0 to 42.0) | 35.0 (29.0 to 41.7) |
| 15 to 19 | 7650 (2.5) | 4247 (3.6) | 1694 (1.8) | 707 (1.6) | 1002 (2.0) |
| 0 to 29 | 86,595 (28.4) | 37,506 (31.6) | 24,741 (27.0) | 11,112 (25.2) | 13,236 (25.9) |
| 30 to 39 | 114,317 (37.4) | 41,350 (34.9) | 34,710 (37.8) | 17,531 (39.8) | 20,726 (40.6) |
| 40 to 49 | 63,747 (20.9) | 22,380 (18.9) | 20,080 (21.9) | 9907 (22.5) | 11,380 (22.3) |
| 50+ | 33,134 (10.8) | 13,097 (11.0) | 10,563 (11.5) | 4772 (10.8) | 4702 (9.2) |
| Point of entry for care | |||||
| VCT | 109,535 (35.9) | 41,878 (35.3) | 34,409 (37.5) | 15,797 (35.9) | 17,451 (34.2) |
| PMTCT | 18,401 (6.0) | 11,563 (9.8) | 4316 (4.7) | 1364 (3.1) | 1158 (2.3) |
| TB/HIV | 8674 (2.8) | 2818 (2.4) | 2469 (2.7) | 1431 (3.3) | 1956 (3.8) |
| Inpatient | 15,358 (5.0) | 4765 (4.0) | 4276 (4.7) | 2596 (5.9) | 3721 (7.3) |
| Outpatient | 48,289 (15.8) | 16,343 (13.8) | 14,981 (16.3) | 7849 (17.8) | 9116 (17.9) |
| Other | 80,566 (26.4) | 31,826 (26.8) | 23,920 (26.1) | 11,312 (25.7) | 13,508 (26.5) |
| Unknown | 24,620 (8.1) | 9387 (7.9) | 7417 (8.1) | 3680 (8.4) | 4136 (8.1) |
| WHO stage at ART | |||||
| I | 42,395 (17.3) | 21,768 (23.0) | 12,993 (17.5) | 3877 (10.9) | 3757 (9.1) |
| II | 64,645 (26.3) | 25,641 (27.1) | 22,072 (29.7) | 8569 (24.0) | 8363 (20.4) |
| III | 114,107 (46.5) | 39,790 (42.1) | 33,277 (44.8) | 19,003 (53.2) | 22,037 (53.6) |
| IV | 24,432 (9.9) | 7280 (7.7) | 5933 (8.0) | 4282 (12.0) | 6937 (16.9) |
| Missing WHO stage at ART | 59,864 (19.6) | 24,101 (20.3) | 17,513 (19.1) | 8298 (18.8) | 9952 (19.5) |
| Year of enrolment in HIV care | |||||
| 2005 to 2006 | 44,334 (14.5) | 12,956 (10.9) | 15,165 (16.5) | 7458 (16.9) | 8755 (17.2) |
| 2007 to 2008 | 85,214 (27.9) | 27,542 (23.2) | 28,640 (31.2) | 13,704 (31.1) | 15,328 (30.0) |
| 2009 to 2010 | 83,188 (27.2) | 33,152 (28.0) | 24,863 (27.1) | 11,586 (26.3) | 13,587 (26.6) |
| 2011 to 2012 | 61,322 (20.1) | 27,741 (23.4) | 16,252 (17.7) | 7859 (17.8) | 9470 (18.6) |
| 2012 to 2014 | 31,385 (10.3) | 17,189 (14.5) | 6868 (7.5) | 3422 (7.8) | 3906 (7.7) |
| Year initiated ART | |||||
| 2005 to 2006 | 33,122 (10.8) | 7690 (6.5) | 11,370 (12.4) | 6386 (14.5) | 7676 (15.0) |
| 2007 to 2008 | 75,350 (24.7) | 20,937 (17.7) | 26,656 (29.0) | 13,138 (29.8) | 14,619 (28.6) |
| 2009 to 2010 | 80,906 (26.5) | 29,153 (24.6) | 26,139 (28.5) | 11,864 (26.9) | 13,750 (26.9) |
| 2011 to 2012 | 71,257 (23.3) | 33,115 (27.9) | 19,016 (20.7) | 8696 (19.8) | 10,430 (20.4) |
| 2012 to 2014 | 43,614 (14.3) | 26,721 (22.5) | 8472 (9.2) | 3898 (8.9) | 4523 (8.9) |
| 2015 | 1194 (0.4) | 964 (0.8) | 135 (0.1) | 47 (0.1) | 48 (0.1) |
ART, antiretroviral therapy; IQR, interquartile range; WHO, World Health Organization.